Bure Growth has increased its shareholding in BioLamina to 52% through a transaction involving the sale of shares by existing shareholders to Bure Growth and Lauxera Capital, a healthcare specialist investor, among others.
BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. Since the inception in 2009, the company has developed unique expertise in the development and production of recombinant human laminins, which are key proteins enabling researchers and biopharma to differentiate, edit and cultivate both stem cells and other cells.
The value of BioLamina’s different laminin products have been proven in a multitude of publications, as well as in the hands of biotechs and pharma companies active in the development of cell therapies and will continue to provide vital support from early research to commercialization of tomorrow’s therapies.
Based in Sundbyberg (Sweden) and Boston (USA), the company currently has approximately 70 employees.
The company’s main shareholders include Bure Equity (via Bure Growth), the Tryggvason family (founders), Lauxera Capital Partners and Northislet.
Bure warmly welcomes Lauxera as a new shareholder in BioLamina. We are enthusiastic about collaborating to support the company as it pursues its exciting growth plan. The transaction does not involve the infusion of primary capital.